 |
Ashvattha Therapeutics
Last updated: July 11, 2025
Founder Jeffrey Cleland
USA | Funding: $148M (+)
Website: http://avttx.com/
Ashvattha Therapeutics develops therapy thar selectively targets hyper-inflammatory macrophages responsible for excessive cytokine production in severe COVID-19 patients.
Website: http://avttx.com/
Ashvattha Therapeutics develops therapy thar selectively targets hyper-inflammatory macrophages responsible for excessive cytokine production in severe COVID-19 patients.
